These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30299600)

  • 1. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation.
    Zabel M; Sticherling C; Willems R; Lubinski A; Bauer A; Bergau L; Braunschweig F; Brugada J; Brusich S; Conen D; Cygankiewicz I; Flevari P; Taborsky M; Hansen J; Hasenfuß G; Hatala R; Huikuri HV; Iovev S; Kääb S; Kaliska G; Kasprzak JD; Lüthje L; Malik M; Novotny T; Pavlović N; Schmidt G; Shalganov T; Sritharan R; Schlögl S; Szavits Nossan J; Traykov V; Tuinenburg AE; Velchev V; Vos MA; Willich SN; Friede T; Svendsen JH; Merkely B;
    ESC Heart Fail; 2019 Feb; 6(1):182-193. PubMed ID: 30299600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project.
    Zabel M; Schlögl S; Lubinski A; Svendsen JH; Bauer A; Arbelo E; Brusich S; Conen D; Cygankiewicz I; Dommasch M; Flevari P; Galuszka J; Hansen J; Hasenfuß G; Hatala R; Huikuri HV; Kenttä T; Kucejko T; Haarmann H; Harden M; Iovev S; Kääb S; Kaliska G; Katsimardos A; Kasprzak JD; Qavoq D; Lüthje L; Malik M; Novotný T; Pavlović N; Perge P; Röver C; Schmidt G; Shalganov T; Sritharan R; Svetlosak M; Sallo Z; Szavits-Nossan J; Traykov V; Vandenberk B; Velchev V; Vos MA; Willich SN; Friede T; Willems R; Merkely B; Sticherling C;
    J Electrocardiol; 2019; 57S():S34-S39. PubMed ID: 31526572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study.
    Zabel M; Willems R; Lubinski A; Bauer A; Brugada J; Conen D; Flevari P; Hasenfuß G; Svetlosak M; Huikuri HV; Malik M; Pavlović N; Schmidt G; Sritharan R; Schlögl S; Szavits-Nossan J; Traykov V; Tuinenburg AE; Willich SN; Harden M; Friede T; Svendsen JH; Sticherling C; Merkely B;
    Eur Heart J; 2020 Sep; 41(36):3437-3447. PubMed ID: 32372094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICD risk stratification studies - EU-CERT-ICD and the European perspective.
    Seegers J; Bergau L; Tichelbäcker T; Malik M; Zabel M
    J Electrocardiol; 2016; 49(6):831-836. PubMed ID: 27623399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of Prognostic Value of T-Wave Alternans for Implantable Cardioverter-Defibrillator Benefit in Primary Prevention.
    Pelli A; Kenttä TV; Junttila MJ; Huber C; Schlögl S; Zabel M; Malik M; Willems R; Vos MA; Harden M; Friede T; Sticherling C; Huikuri HV;
    J Am Heart Assoc; 2024 Jun; 13(11):e032465. PubMed ID: 38804218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study.
    Pelli A; Junttila MJ; Kenttä TV; Schlögl S; Zabel M; Malik M; Reichlin T; Willems R; Vos MA; Harden M; Friede T; Sticherling C; Huikuri HV;
    Europace; 2022 May; 24(5):774-783. PubMed ID: 34849744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study.
    Bauer A; Klemm M; Rizas KD; Hamm W; von Stülpnagel L; Dommasch M; Steger A; Lubinski A; Flevari P; Harden M; Friede T; Kääb S; Merkely B; Sticherling C; Willems R; Huikuri H; Malik M; Schmidt G; Zabel M;
    Lancet; 2019 Oct; 394(10206):1344-1351. PubMed ID: 31488371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated electrocardiographic quantification of myocardial scar in patients undergoing primary prevention implantable cardioverter-defibrillator implantation: Association with mortality and subsequent appropriate and inappropriate therapies.
    Reichlin T; Asatryan B; Vos MA; Willems R; Huikuri HV; Junttila MJ; Schlögl SC; Hnatkova K; Schaer BA; Malik M; Zabel M; Sticherling C;
    Heart Rhythm; 2020 Oct; 17(10):1664-1671. PubMed ID: 32428669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.
    Platonov PG; Haugaa KH; Bundgaard H; Svensson A; Gilljam T; Hansen J; Madsen T; Holst AG; Carlson J; Lie ØH; Kvistholm Jensen M; Edvardsen T; Jensen HK; Svendsen JH
    Am J Cardiol; 2019 Apr; 123(7):1156-1162. PubMed ID: 30678832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary benefit-harm profile over two decades in primary prophylactic ICD-therapy.
    Kleemann T; Strauss M; Kouraki K; Lampropoulou E; Fendt A; Werner N; Zahn R
    Clin Cardiol; 2019 Oct; 42(10):866-872. PubMed ID: 31317573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.
    Wolff G; Lin Y; Karathanos A; Brockmeyer M; Wolters S; Nowak B; Fürnkranz A; Makimoto H; Kelm M; Schulze V
    Clin Res Cardiol; 2017 Jul; 106(7):501-513. PubMed ID: 28213711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
    Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
    Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls.
    Pezawas T; Diedrich A; Winker R; Robertson D; Richter B; Wang L; Byrne DW; Schmidinger H
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1101-8. PubMed ID: 25262115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
    Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
    Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of implantable cardioverter defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments.
    Inama G; Pedrinazzi C; Landolina M; Oliva F; Senni M; Proclemer A; Berisso MZ; Pirelli S;
    J Cardiovasc Med (Hagerstown); 2012 Nov; 13(11):675-83. PubMed ID: 22002257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
    Randles DA; Hawkins NM; Shaw M; Patwala AY; Pettit SJ; Wright DJ
    Europace; 2014 Jul; 16(7):1015-21. PubMed ID: 24351884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.